RA0725

antibody from Oursmab

Targeting: TGFB2

Western blot (Supportive data in Antibodypedia)

ELISA (Supportive data in Antibodypedia)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0725

Provider

Oursmab

Product name

Lerdelimumab (Biosimilar Reference Antibody) (TGFB2)

Antibody type

Monoclonal

Description

Lerdelimumab (also known as CAT-152) is a human monoclonal antibody developed to specifically neutralize transforming growth factor-beta 2 (TGF-¦Â2), one of the predominant isoforms of TGF-¦Â found in the eye. It was designed as a local (intraocular) therapy to prevent the scarring process (fibrosis) that occurs after glaucoma filtration surgery. By blocking TGF-¦Â2, lerdelimumab aimed to inhibit the activation, proliferation, and collagen production of fibroblasts and myofibroblasts at the surgical site, thereby improving surgical outcomes by maintaining an open drainage channel. Although it showed promise in early clinical trials, its development for this indication has been discontinued.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.

Western blot

Supportive validation

Submitted by

Oursmab (provider)

Main image

Experimental details

Lerdelimumab (Biosimilar Reference Antibody) (TGFB2)-RA0725-Oursmab determined by SDS-PAGE. The purity of the protein is greater than 98%.

ELISA

Supportive validation

Submitted by

Oursmab (provider)

Main image

Experimental details

ELISA plate pre-coated Antigen protein, can bind Lerdelimumab (Biosimilar Reference Antibody) (TGFB2)-RA0725 in a linear range of 0.18¨C15 ng/mL.